Investor Relations

Company Overview

At Sutro, we are advancing a cutting-edge, next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, our cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, we aim to overcome treatment resistance and redefine what’s possible in cancer therapy. Our pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.